What MSD Romania does

MSD Romania operates as Merck Sharp & Dohme Romania SRL, a wholly-owned subsidiary of Merck & Co., Inc. (NYSE: MRK) and the local affiliate of the global pharmaceutical company known as MSD outside North America. The Romanian entity commercializes the parent company's innovative prescription medicines across four primary therapeutic areas: oncology, vaccines, infectious diseases, and cardiovascular/metabolic diseases. It serves the Romanian market and, following a regional restructuring into the MEDEBA cluster, extends coverage to the Republic of Moldova. The subsidiary employs approximately 136 staff focused on medical affairs, market access, regulatory, and commercial field operations supporting physicians, hospitals, and the national health insurance system.

The company's core product portfolio mirrors the parent company's global launches in oncology and vaccines, with established positions in immuno-oncology (Keytruda-class therapies inherited from group development), HPV and other vaccines, HIV antiretrovirals (expanded via the 2021 Gilead partnership), and chronic disease treatments. Its business model is a classic multinational pharma go-to-market: it sells reimbursed prescription medicines primarily through the National Health Insurance House (CNAS/NHIH) framework, with secondary channels through hospital tenders, retail pharmacies, and physician-detailing field forces. Revenue mechanics depend on obtaining and maintaining reimbursement listings, winning hospital tenders, and driving physician adoption — a model exposed to public-procurement cycles and reference-pricing pressure. No local manufacturing is indicated; products are supplied through the group's regional and global supply chain.

Beyond commercial operations, MSD Romania has built a public-health and CSR footprint, including the MSD for Mothers partnership with World Vision Romania (2016) targeting maternal mortality, a $50,000 cancer health-literacy research grant with Babeș-Bolyai University (2023), and participation in the AMR Industry Alliance (2016) and AMR Action Fund (2020). In 2023 the company achieved Best Place to Work certification, indicating investment in employer brand in a competitive CEE pharma talent market. Following the May 2026 leadership transition — Conor Dempsey replacing Marcelo Pascual Morales as Managing Director — the affiliate is positioned for continued emphasis on oncology, vaccines, and cardio-metabolic franchises within Romania and Moldova.

Name

MSD Romania

Legal name

Merck Sharp & Dohme Romania SRL

Website

https://msd.ro

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

MSD Romania (Merck Sharp & Dohme Romania SRL) is the Romanian and Moldovan affiliate of Merck & Co., commercializing innovative prescription medicines in oncology, vaccines, infectious diseases, and cardiovascular/metabolic diseases through NHIH reimbursement, hospital channels, and physician field forces.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN)

akta.pro secondary industry

Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Prescription pharmaceuticals
• Vaccine development
• Oncology therapies
• Infectious disease treatments
• Animal health products

Headquarters

HQ city

București

HQ country

Romania

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Prescription Medicines: MSD generates revenue through prescription pharmaceutical products including oncology treatments, cardiovascular medications, diabetes treatments, and other therapeutic areas. Revenue is generated through healthcare provider prescriptions and hospital procurement.
2. Vaccines: Revenue from vaccine products including HPV vaccine, pediatric vaccines (rotavirus, measles-mumps-rubella), and adult vaccines. Distributed approximately 203 million doses globally in 2022.
3. Hospital Acute Care Products: Products for hospital settings including antibiotics and antifungics for inpatient care, contributing to the Hospital Acute Care division.
4. Animal Health Products: MSD Animal Health division provides veterinary products and vaccines, operating as a separate business unit with global presence.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

MSD Romania is the Romanian subsidiary of Merck & Co., Inc., operating as a biopharmaceutical company that develops, manufactures, and distributes prescription medicines, vaccines, and animal health products across therapeutic areas including oncology, vaccines, infectious diseases (HIV, hepatitis C, antibiotics, antifungals), cardiovascular and metabolic diseases (including type 2 diabetes), and hospital acute care. The company sells primarily to hospitals, healthcare providers, government health programs, and pharmacies, with a separate MSD Animal Health division serving veterinarians and livestock producers.

Product overview

MSD Romania operates as the Romanian subsidiary of Merck Sharp & Dohme (MSD), a global biopharmaceutical company known as Merck & Co. in the US and Canada. The company offers a comprehensive portfolio of prescription medicines and vaccines across multiple therapeutic areas including oncology (with treatments for 30+ cancer types), vaccines (protecting against 20+ diseases with 203M doses distributed globally in 2022), infectious diseases (HIV with 35 years of research, Ebola, antibiotics since 1942), cardiovascular and metabolic diseases (including diabetes), and hospital care products. MSD also operates an Animal Health division. The company's research and development process encompasses drug discovery, pre-clinical development, clinical development, and real-world evidence generation through its CORE center. With over 130 years of pharmaceutical innovation, MSD Romania focuses on bringing innovative medicines to the Romanian market through its network of operations in Romania and the Republic of Moldova.

Differentiator

Problem solved

Functional benefit

Brands

• MSD for Mothers: A 10-year, $500 million initiative that applies MSD's scientific expertise and business resources to reduce maternal mortality globally. In Romania, MSD for Mothers partnered with World Vision Romania in 2016.
• MSD Animal Health
• MSD Wellcome Trust Hilleman Laboratories

Products and services

• Oncology Therapies

Quantifiable outcome

• 400,000+ oncology patients treated in the last 5 years
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Universitatea Babeș-Bolyai (UBB)coreStrategic or Co-development Partner · 27 March 2023Departamentul de Sănătate Publică al Universității Babeș-Bolyai and MSD România launched a health policy research project analyzing how improving cancer literacy can reduce inequities in cancer treatment. The project, funded with $50,000 through MSD's Global Cancer Health Policy Grants Program, will develop policy recommendations to improve access to information and medical services for oncology patients. Implemented over 12 months using evidence-based and personalized approaches in the bio-psycho-social model framework.
• Onco-alliance (Slovakia)coreStrategic or Co-development Partner · 1 November 2022Strategic oncology alliance supporting implementation of European-funded projects worth over 8 million euros for oncology infrastructure and digitization. Projects focused on colon cancer, breast cancer, and lung cancer improvement initiatives.
• Gilead SciencesminorStrategic or Co-development Partner · 1 January 2021MSD entered into an agreement with Gilead to collaborate within the global HIV community in the fight against HIV, combining capabilities to address this ongoing public health challenge.
• Antimicrobial Resistance (AMR) Action FundminorStrategic or Co-development Partner · 1 January 2020MSD, together with over 20 leading biopharmaceutical companies, launched the AMR Action Fund to make 2-4 new antibiotics available to patients by the end of the decade. This initiative addresses the critical need for new antimicrobial treatments in the face of growing resistance.
• World Vision RomâniacoreStrategic or Co-development Partner · 1 January 2016MSD Romania and World Vision Romania Foundation launched a comprehensive program to reduce maternal mortality in Romania as part of the global MSD for Mothers initiative. The program develops an integrated and innovative model of family planning, reproductive health, and pregnant women assistance services in disadvantaged areas of the country. The global MSD for Mothers initiative is a 10-year, $500 million commitment to reducing maternal mortality globally.
• AMR Industry AllianceminorStrategic or Co-development Partner · 1 January 2016MSD joined the AMR Industry Alliance, a network of over 100 pharmaceutical industry partners working to provide sustainable solutions to help reduce antimicrobial resistance. The alliance represents one of the largest private sector coalitions addressing AMR globally.
• One Health Global Leaders Group on Antimicrobial ResistanceminorStrategic or Co-development PartnerMSD participates as an industry representative in the One Health Global Leaders Group on Antimicrobial Resistance, advocating for a One Health approach to ensure antibiotics remain an important tool for improving and maintaining human and animal health.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Sanofi Romania: Romanian subsidiary of Sanofi S.A., with strong overlap in vaccines, diabetes, and rare diseases. Comparable to MSD Romania in pediatric and adult vaccine portfolios and in diabetes/cardio-metabolic therapeutic areas.
• Roche Romania: Romanian subsidiary of Roche Group with a strong oncology and diagnostics overlap. Directly comparable to MSD Romania in oncology positioning, hospital channel focus, and participation in national cancer control planning.
• Novartis Romania: Romanian subsidiary of Novartis AG covering oncology, cardiovascular, and immunology portfolios. Comparable to MSD Romania as a top-tier multinational pharma subsidiary competing for hospital formularies and reimbursement in Romania.
• Johnson & Johnson (Janssen) Romania: Romanian pharmaceutical operations of Johnson & Johnson covering oncology, immunology, and infectious diseases. Directly comparable to MSD Romania across hospital specialty channels and government health authority engagement.
• Eli Lilly Romania: Romanian subsidiary of Eli Lilly and Company with a strong diabetes and oncology footprint. Overlaps directly with MSD Romania's diabetes and oncology franchises and competes for the same specialist prescriber base and reimbursement decisions.
• Bayer Romania: Romanian subsidiary of Bayer AG spanning pharmaceuticals and consumer health, including cardiology and women's health. Comparable to MSD Romania as a multinational pharma subsidiary with hospital and pharmacy channel presence in Romania.
• Pfizer Romania: Romanian subsidiary of Pfizer Inc., operating across vaccines, oncology, infectious diseases, and internal medicine. Closely comparable to MSD Romania in scale, therapeutic breadth, and reliance on government vaccination tenders and hospital procurement in Romania.
• AstraZeneca Romania: Romanian subsidiary of AstraZeneca PLC covering oncology, cardiovascular/metabolic, and respiratory. Overlaps with MSD Romania's oncology and cardio-metabolic focus and competes for the same hospital and government channels.
• AbbVie Romania: Romanian subsidiary of AbbVie Inc., with strong immunology and oncology overlap. Comparable to MSD Romania as a specialty pharma subsidiary competing for hospital reimbursement and prescriber share in Romania.
• GSK Romania: Romanian subsidiary of GSK plc with significant overlap in vaccines (HPV, pediatric, travel) and infectious disease. Directly comparable to MSD Romania in national vaccination program participation and respiratory/specialty pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/MSD_Romania
• YouTubeyoutube.com/channel/UCA7IL7Fek_8_btjlwxFb5NQ
• LinkedInlinkedin.com/company/msd-romania

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSD Romania